Horizon Therapeutics PLC (NASDAQ:HZNP)
| 70.52 Delayed Data As of Nov 27 |  +1.62 / +2.35%Today’s Change | 23.81 Today|||52-Week Range 86.67 | +94.81% Year-to-Date |
Latest HZNP News | Press Releases
| HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts Nov 27 / Zacks.com - Paid Partner Content | John Paulson Buys Lear, Sells TD Ameritrade Nov 23 / GuruFocus News - Paid Partner Content |
| Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology Nov 24 / Zacks.com - Paid Partner Content | Is Horizon Therapeutics (HZNP) a Worthy Stock Now? Nov 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 68.90 |
| Today’s open | 69.95 |
| Day’s range | 69.90 - 70.95 |
| Volume | 114,583 |
| Average volume (3 months) | 2,343,853 |
| Market cap | $15.5B |
Data as of 12:59pm ET, 11/27/2020
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +85.91% |
| Earnings growth (next 5 years) | +30.12% |
| Revenue growth (last year) | +7.66% |
| P/E ratio | 17.8 |
| Price/Sales | 5.71 |
| Price/Book | 6.04 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CTLTCatalent Inc | +2.62 | +2.77% |
| ALNYAlnylam Pharmaceutic... | +4.40 | +3.51% |
| INCYIncyte Corp | +2.16 | +2.66% |
| ---- |
Data as of 1:00pm ET, 11/27/2020
Financials
| Next reporting date | March 3, 2021 |
| EPS forecast (this quarter) | $1.02 |
| Annual revenue (last year) | $1.3B |
| Annual profit (last year) | $573.0M |
| Net profit margin | 44.08% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Dublin, Dublin |
Forecasts
